• People

    Advanced Search

  • Services
  • All Services


  • As of January 2026, Stark & Stark is no longer accepting inquiries for this litigation.


    What Are the Oxbryta Recall Lawsuits About?

    Oxbryta (also known as voxelotor) is a medication used to treat sickle cell disease. Oxbryta has been recalled because it has been shown to cause vaso-occlusive crisis. The drugmaker Pfizer developed and sold Oxbryta. In 2019, Oxbryta received accelerated approval from the United States Food and Drug Administration (FDA) for the treatment of sickle cell disease in patients 12 years of age and older. In 2021, the FDA granted accelerated approval of Oxbryta for the treatment of sickle cell disease in patients as young as 4 years of age.

    In September 2024, it was found that Oxbryta was linked to vaso-occlusive crisis in sickle cell disease sufferers, forcing Pfizer to recall all lots of Oxbryta. This has led to multiple lawsuits being filed by Oxbryta patients diagnosed with vaso-occlusive crisis.

    Stark & Stark is a national law firm pursuing thousands of cases throughout the country. We are not a marketing group. Stark & Stark has been in business for over since 1933 and has roughly 100 experienced attorneys in offices located throughout New Jersey, Pennsylvania, and New York, ready to talk to you about your potential claim. Please, let us help you.

    What Are the Side Effects of Oxbryta?

    Oxbryta has several side effects, but the current lawsuits against Pfizer involve vaso-occlusive crisis. Vaso-occlusive crisis is severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues. Studies show that patients treated with Oxbryta were more likely to suffer vaso-occlusive crisis than patients not treated with Oxbryta. These studies also showed that there were more deaths in patients treated with Oxbryta. Therefore, it was determined that the benefit of Oxbryta did not outweigh the substantial risks and Oxbryta was subject to a complete recall from the market.

    If you are a sickle cell disease patient, have taken Oxbryta, and have been diagnosed with vaso-occlusive crisis, please contact Stark & Stark. There is no obligation to you and Stark & Stark’s Oxbryta recall attorneys are standing by to answer your questions and help you assess your options going forward.

    Do I Have an Oxbryta Vaso-Occlusive Crisis Injury Claim?

    Postmarketing studies show that Oxbryta is linked to vaso-occlusive crisis, causing a total recall of Oxbryta in September 2024. Vaso-occlusive crisis is an extremely painful and serious condition, frequently leading to emergency room visits and/or extended hospitalizations. Vaso-occlusive crisis is caused by affected blood cells unable to freely flow through a patient’s blood vessels resulting in severe pain. Vaso-occlusive crisis can start suddenly, be mild to severe, and can last for any length of time. Pain can occur in any part of the body, but commonly occurs in the hands, feet, chest, and back.

    You may be entitled to compensation if you or a loved one:

    • Are a sickle cell disease patient;
    • Have taken Oxbryta; and
    • Have been diagnosed with vaso-occlusive crisis;

    While we insist that you do not discontinue taking any medications before speaking with your doctor, we strongly recommend that you seek counsel experienced in Oxbryta vaso-occlusive crisis claims and injuries. Stark & Stark’s Oxbryta recall attorneys are actively investigating Oxbryta vaso-occlusive crisis claims and seeking settlements on behalf of patients injured by this potentially defective drug. Contact us at no cost to you.

    Have Oxbryta Recall Class Action Lawsuits Been Filed?

    While Oxbryta was not recalled until September 2024, claims to date allege that Pfizer knew or should have known of these dangers for many years and failed to warn patients. Many Oxbryta vaso-occlusive crisis claims have been made against Pfizer across the country, but those claims have not yet been consolidated. We expect the volume of claims to rise in the coming months, potentially giving rise to a Multidistrict Litigation (MDL). Stark & Stark is experienced in complex federal litigation throughout the nation and has successfully litigated thousands of cases through the MDL litigation and settlement process.

    Stark & Stark is committed to holding drug manufacturers liable when their products improperly endanger the public. Stark & Stark’s Oxbryta vaso-occlusive crisis attorneys are experienced in defective drug litigations throughout the nation and in negotiating with pharmaceutical settlement representatives. We are not a marketing group. Stark & Stark is a law firm comprised of experienced trial lawyers. If you have an Oxbryta recall claim, or you are uncertain and have questions about injuries that you may have suffered because of Pfizer Oxbryta, the attorneys at Stark & Stark can help. Contact us now for a free consultation.

    Contact an Oxbryta Vaso-Occlusive Crisis Lawyer to Assess Your Claim.

    If you or a member of your family has suffered vaso-occlusive crisis injuries from Pfizer Oxbryta, you may be entitled to compensation through litigation or via settlement. Please contact Stark & Stark to speak with one of our Oxbryta recall attorneys, free of charge, who can help walk you through the settlement and lawsuit process and assess any claims that you may have.

    Please contact Stark & Stark today, free of charge. But do not wait, because there are different deadlines and statutes of limitations that apply to your claims.

    Speak with an Experienced Attorney Today

    Key Contacts

    Martin P. Schrama
    609.895.7261

    Firm Highlights

    Stark & Stark Shareholder Deborah S. Dunn, Esq. Installed as 2nd Vice President and Diversity Officer of the New Jersey Association for Justice for 2026–2027

    Stark & Stark is proud to announce that Shareholder Deborah S. Dunn, Esq. has been installed as 2nd Vice President and Diversity Officer of the...

    Stark & Stark Recognized with Community Partner Award by Mercer County Community College Foundation

    Stark & Stark is proud to announce that the firm has been recognized with the Community Partner Award by the Mercer County Community College...

    Carin A. O’Donnell, Esq. Inducted as 2026-2027 President of the Pennsylvania Association for Justice

    Stark & Stark is proud to announce that Carin A. O'Donnell, Esq. was sworn in as the 2026-2027 President of the Pennsylvania Association for...

    Stark & Stark’s Thomas S. Onder, Esq. Receives 2026 ICSC Trustees’ Distinguished Service Award

    Stark & Stark is proud to announce that Thomas S. Onder, Esq., Shareholder and Chair of the Firm’s Shopping Center & Retail Development...

    Stark & Stark’s Joseph H. Lemkin Esq., Named 2026 Professional Lawyer of the Year for the Jewish Bar Association of New Jersey

    Stark & Stark is proud to announce that Joseph H. Lemkin Esq. has been selected by the New Jersey Commission on Professionalism in the Law as...

    Our Values Remain: A Message on the Closing of Diversity Lab

    Stark & Stark is saddened and disappointed to learn that Diversity Lab, the organization that created and manages the Mansfield Certification...

    Congratulations to Shareholder Bhaveen R. Jani, Esq. on his Installation as Treasurer of the Middlesex County Bar Foundation

    Stark & Stark is proud to announce that Shareholder Bhaveen R. Jani, Esq. has been installed as Treasurer of the Middlesex County Bar Foundation,...

    Denise Mariani, Esq., and Jonathan Lauri, Esq. Secure $750,000 Jury Verdict Against Hamilton Healthcare and Rehabilitation Center

    It is our pleasure to announce that Denise Mariani, Esq., and Jonathan Lauri, Esq., secured a $750,000 jury verdict on behalf of a nursing home...

    Stark & Stark Welcomes 2026 Summer Law Clerks

    Stark & Stark is proud to announce its 10th Annual Summer Law Clerk Program. Five Summer Law Clerks will join the firm from June through July...

    Retail Development Team Secures Major Recovery for Landlord Client Amid Bankruptcy Dispute

    Our Shopping Center and Retail Development Group recently secured a multi-million-dollar settlement for a commercial landlord client' s property...

    Jeffrey A. Krawitz, Esq. and Catherine Foley, Esq. Secure $950,000 Settlement in Surgical Malpractice Matter

    Jeffrey A. Krawitz, Esq. and Catherine Foley, Esq. recently secured a confidential $950,000 settlement in a surgical malpractice case. “This...

    Victoria Wilton, Esq. Selected to Serve on New Jersey State Bar Association Family Law Executive Committee

    We are proud to announce that Victoria Wilton, Esq. has been selected to serve on the New Jersey State Bar Association Family Law Executive Committee...